- Home
- MDAI vs NRXS Comparison
MDAI vs NRXS Comparison
Compare MDAI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDAI | NRXS |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDAI | NRXS |
|---|---|---|
| Price | $1.96 | $7.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 969.9K | 159.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | $23.50 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.18 | $2.20 |
| 52 Week High | $3.21 | $9.33 |
Technical Indicators
Market Signals| Indicator | MDAI | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 42.63 |
| Support Level | $1.78 | $6.51 |
| Resistance Level | $2.89 | $7.85 |
| Average True Range (ATR) | 0.26 | 0.47 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 1.94 | 14.87 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).